Structural insights into SARS-CoV-2 proteins
The unprecedented scale of the ongoing COVID-19 pandemic has catalyzed an intense
effort of the global scientific community to unravel different aspects of the disease in a short …
effort of the global scientific community to unravel different aspects of the disease in a short …
Structural basis of potential inhibitors targeting SARS-CoV-2 main protease
The Coronavirus disease-19 (COVID-19) pandemic is still devastating the world causing
significant social, economic, and political chaos. Corresponding to the absence of globally …
significant social, economic, and political chaos. Corresponding to the absence of globally …
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir
Y Duan, H Zhou, X Liu, S Iketani, M Lin, X Zhang… - Nature, 2023 - nature.com
Nirmatrelvir is a specific antiviral drug that targets the main protease (Mpro) of SARS-CoV-2
and has been approved to treat COVID-19,. As an RNA virus characterized by high mutation …
and has been approved to treat COVID-19,. As an RNA virus characterized by high mutation …
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
There is an urgent need for antiviral agents that treat severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection. We screened a library of 1900 clinically safe drugs …
coronavirus 2 (SARS-CoV-2) infection. We screened a library of 1900 clinically safe drugs …
[HTML][HTML] Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
L Fu, F Ye, Y Feng, F Yu, Q Wang, Y Wu, C Zhao… - Nature …, 2020 - nature.com
COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global
public health. The coronavirus main protease (M pro, also called 3CLpro) is essential for …
public health. The coronavirus main protease (M pro, also called 3CLpro) is essential for …
[HTML][HTML] Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
A new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), is the aetiological agent responsible for the 2019–2020 viral pneumonia outbreak of …
2), is the aetiological agent responsible for the 2019–2020 viral pneumonia outbreak of …
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the etiological agent
responsible for the global COVID-19 (coronavirus disease 2019) outbreak. The main …
responsible for the global COVID-19 (coronavirus disease 2019) outbreak. The main …
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome–coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug …
syndrome–coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug …
α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment
L Zhang, D Lin, Y Kusov, Y Nian, Q Ma… - Journal of medicinal …, 2020 - ACS Publications
The main protease of coronaviruses and the 3C protease of enteroviruses share a similar
active-site architecture and a unique requirement for glutamine in the P1 position of the …
active-site architecture and a unique requirement for glutamine in the P1 position of the …
Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site
Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the pathogen
that causes the disease COVID-19, produces replicase polyproteins 1a and 1ab that …
that causes the disease COVID-19, produces replicase polyproteins 1a and 1ab that …